Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jan 6;12(3):233–242. doi: 10.1093/neuonc/nop027

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2010. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 3. — MR images from case 3. (A, C, E, and G) Axial postcontrast T1-weighted MR images. (B, D, F, and H) FLAIR MR images. (A and B) Images taken 14 months after surgery, radiation therapy, and chemotherapy for bifrontal lobe glioblastoma that infiltrated across the genus of the corpus callosum. The enhancing area was seen in the right frontal lobe, capping and infiltrating the right frontal horn (arrow in A). Nonenhancing tumor within the corpus callosum (arrows in B) was better visualized in the FLAIR image. (C and D) Images taken 62 days after beginning bevacizumab therapy. The enhancing area within the right frontal lobe showed significant decrease (arrow in C), but the nonenhancing tumor showed progression (arrows in D). (E and F) Images taken 117 days after beginning bevacizumab therapy. The enhancing area within the right frontal lobe showed further decrease, but the nonenhancing tumor (arrows in F) showed progression. (G and H) Images taken 175 days after initiating bevacizumab treatment. Marked tumor progression was evident by an increase in nonenhancing tumor (arrows in H) and with a small component of enhancing tumor (arrow in G) producing subfalcine herniation. After subtotal resection of the tumor on May 21, 2007, it was histologically proven to be glioblastoma.